Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Baxter
McKesson
Mallinckrodt
Harvard Business School

Last Updated: June 28, 2022

CLINICAL TRIALS PROFILE FOR PEMIGATINIB


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Pemigatinib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02393248 ↗ Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Recruiting Incyte Corporation Phase 1/Phase 2 2015-02-27 The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies. This study will have three parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).
NCT02872714 ↗ A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) Active, not recruiting Incyte Corporation Phase 2 2017-01-12 The purpose of this study is to evaluate the overall response rate (ORR) of pemigatinib as a monotherapy in the treatment of metastatic or surgically unresectable urothelial carcinoma harboring FGF/FGFR alterations.
NCT02924376 ↗ Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202) Completed Incyte Corporation Phase 2 2017-01-16 The purpose of this study is evaluate the efficacy of pemigatinib in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.
NCT03011372 ↗ A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203) Recruiting Incyte Corporation Phase 2 2017-04-25 The purpose of this study is to evaluate the efficacy and safety of pemigatinib (INCB054828) in subjects with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1 rearrangement.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pemigatinib

Condition Name

Condition Name for Pemigatinib
Intervention Trials
Urothelial Carcinoma 3
Cholangiocarcinoma 3
Solid Tumor 3
Urothelial Cancer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pemigatinib
Intervention Trials
Neoplasms 7
Carcinoma 6
Cholangiocarcinoma 5
Carcinoma, Transitional Cell 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pemigatinib

Trials by Country

Trials by Country for Pemigatinib
Location Trials
United States 187
Italy 19
Japan 16
France 16
United Kingdom 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pemigatinib
Location Trials
Texas 10
Arizona 9
North Carolina 8
Georgia 8
Florida 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pemigatinib

Clinical Trial Phase

Clinical Trial Phase for Pemigatinib
Clinical Trial Phase Trials
Phase 3 1
Phase 2 21
Phase 1/Phase 2 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pemigatinib
Clinical Trial Phase Trials
Recruiting 15
Not yet recruiting 5
Active, not recruiting 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pemigatinib

Sponsor Name

Sponsor Name for Pemigatinib
Sponsor Trials
Incyte Corporation 17
National Cancer Institute (NCI) 2
Academic and Community Cancer Research United 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pemigatinib
Sponsor Trials
Industry 22
Other 18
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Medtronic
Harvard Business School
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.